NCT00989872View on ClinicalTrials.gov

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

Not specified

Conditions
Skin and Soft Tissue InfectionsMethicillin-resistant Staphylococcus Aureus
Interventions
DRUG

EDP-322

Trial Locations (1)

Unknown

PPD Phase I Unit, Austin

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT00989872 - Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers | Biotech Hunter | Biotech Hunter